BIOSENIC SA (BIOS.BR) Stock Fundamental Analysis

Name: BIOSENIC SA (BIOS) Stock
Brand: BIOSENIC SA
Rating: 2.5 (3 reviews)

Europe - Euronext Brussels - EBR:BIOS - BE0974280126 - Common Stock

0.0025 EUR

0 (0%)

Last: 1/23/2026, 7:00:00 PM

Fundamental Rating

BIOS gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 85 industry peers in the Biotechnology industry. Both the profitability and financial health of BIOS have multiple concerns. BIOS is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

BIOS had negative earnings in the past year.
In the past year BIOS has reported a negative cash flow from operations.
In the past 5 years BIOS always reported negative net income.
BIOS had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of BIOS (-100.55%) is worse than 77.27% of its industry peers.

		Industry Rank	Sector Rank
ROA	-100.55%
ROE	N/A
ROIC	N/A

ROA(3y)-136.98%

ROA(5y)-104.87%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BIOS so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

BIOS has more shares outstanding than it did 1 year ago.
The debt/assets ratio for BIOS is higher compared to a year ago.

2.2 Solvency

BIOS has an Altman-Z score of -16.90. This is a bad value and indicates that BIOS is not financially healthy and even has some risk of bankruptcy.
BIOS has a Altman-Z score of -16.90. This is in the lower half of the industry: BIOS underperforms 79.55% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-16.9

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 0.21 indicates that BIOS may have some problems paying its short term obligations.
The Current ratio of BIOS (0.21) is worse than 92.05% of its industry peers.
BIOS has a Quick Ratio of 0.21. This is a bad value and indicates that BIOS is not financially healthy enough and could expect problems in meeting its short term obligations.
BIOS has a Quick ratio of 0.21. This is amonst the worse of the industry: BIOS underperforms 92.05% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.21
Quick Ratio	0.21

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

BIOS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 92.18%, which is quite impressive.

EPS 1Y (TTM)92.18%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%60.6%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.